Skip to content

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Philadelphia, PA, August 4, 2021 – Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the appointment of three new executive leaders including Scott Greenberg as Chief Operating Officer, Jeffrey Staiger as Senior Vice President of Finance and Business Development, and Michael Tortorici, PharmD, Ph.D. as Vice President of Clinical Pharmacology and Non-Clinical Development. Mr. Greenberg most recently served as Chief Business Officer of Aro, while Mr. Staiger and Dr. Tortorici are new additions to the leadership team. The Company also announced plans to move its headquarters to The Curtis in Philadelphia to accommodate ongoing growth of its operations and staff.    

“The expansion of our leadership team provides Aro with proven executive expertise as we advance our first molecules toward clinical development and continue to scale our organization,” said Susan Dillon, Ph.D., co-founder and Chief Executive Officer of Aro Biotherapeutics. “I am pleased to welcome Jeff and Mike to Aro. They both have deep experience in their respective functional areas that will bring great value to our organization. In his expanded role, Scott and his team will help us build additional business capabilities that will support our future growth.”

Mr. Greenberg joined Aro in 2019 from Roivant Sciences, where he most recently served as Vice President, Head of Operations. Previously, he worked at Celgene Corporation in multiple roles spanning business development, project leadership, strategy, sales and marketing. He began his career in investment banking at Goldman Sachs Group, Inc. and received an MBA from Harvard Business School. 

Mr. Staiger is an accomplished international finance and business development leader having spent more than 13 years at Celgene/Bristol Myers Squibb, in roles that spanned finance, clinical development, corporate strategy, commercial operations, alliance leadership, and business development. Mr. Staiger started his career at PricewaterhouseCoopers, becoming a Certified Public Accountant, and held roles in finance at Quest Diagnostics. He received degrees in Economics and Accounting from Gordon College (MA). 

Dr. Tortorici, PharmD, Ph.D. has 15 years of experience in the pharmaceutical industry in the clinical pharmacology area for small molecules and biologics across a wide range of diseases. He was most recently Executive Director and Head of Clinical Pharmacology at CSL Behring, leading the team responsible for Clinical Pharmacology for all programs in the portfolio. Before that, he worked at Pfizer in Clinical Pharmacology. Dr. Tortorici received his PharmD and Ph.D. in Pharmaceutical Sciences from the University of Pittsburgh School of Pharmacy.

Starting in October 2021, Aro will begin to relocate its operations to The Curtis in Center City Philadelphia. The Curtis is one of the premier locations for the scientific community to develop and pioneer life-saving therapies and attract world-class talent to achieve their goals. The expanded space will be customized to Aro’s needs, providing an ideal location for development of Aro’s proprietary platform of Centyrin – siRNA medicines. Aro plans to complete the move to The Curtis in the first quarter of 2022. 

“We couldn’t be more pleased to be relocating to the historic Curtis building as we enter our next phase of growth,” says Dillon. “The lab and office spaces will help us create a world-class facility, and along with the other building amenities and nearby attractions, The Curtis is ideal for Aro hiring and retaining the very best talent.”

About Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit


Mike Beyer
Sam Brown Inc.

​Source: Aro Biotherapeutics